secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001493152-26-020591
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAffinity stockholders approve reverse stock split, 2024 plan share increase to 1M
--------------------------------------------------------------------------------

- Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-250, at board's discretion.
- Plan amended to increase shares reserved under 2024 Plan from 66,666 to 1,000,000.
- Approved warrant exercise of up to 271,500 shares and anti-dilution adjustments (floor $4.50 for warrants, $3.00 for Series B).
- Six directors elected: Maria Zannes, Steven Girgenti, Peter Knight, Jamie Platt, Roberto Rios, John J. Oppenheimer.
- Ratified WithumSmith+Brown as independent auditor for fiscal year 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226020591/0001493152-26-020591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226020591/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-020591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer